TY - JOUR T1 - Individualized risk trajectories for iron-related adverse outcomes in repeat blood donors JF - medRxiv DO - 10.1101/2021.10.09.21264792 SP - 2021.10.09.21264792 AU - W. Alton Russell AU - David Schienker AU - Brian Custer Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/11/2021.10.09.21264792.abstract N2 - Background Despite a fingerstick hemoglobin requirement and 56-day minimum donation interval, repeat blood donation continues to cause and exacerbate iron deficiency.Study design and methods Using data from the REDS-II Donor Iron Status Evaluation study, we developed multiclass prediction models to estimate the competing risk of hemoglobin deferral and collecting blood from a donor with sufficient hemoglobin but low or absent underlying iron stores. We compared models developed with and without two biomarkers not routinely measured in most blood centers: ferritin and soluble transferrin receptor. We generated and analyzed ‘individual risk trajectories’: estimates of how each donors’ risk developed as a function of the time interval until their next donation attempt.Results With standard biomarkers, the top model had a multiclass area under the receiver operator characteristic curve (AUC) of 77.6% (95% CI 77.3% - 77.8%). With extra biomarkers, multiclass AUC increased to 82.8% (95% CI 82.5% - 83.1%). In the extra biomarkers model, ferritin was the single most important variable, followed by the donation interval. We identified three risk archetypes: ‘fast recoverers’ (<10% risk of any adverse outcome on post-donation day 56), ‘slow recoverers’ (>60% adverse outcome risk on day 56 that declines to <35% by day 250), and ‘chronic high-risk’ (>85% risk of adverse outcome on day 250).Discussion A longer donation interval reduced estimated risk of iron-related adverse events for most donors, but risk remained high for some. Tailoring safeguards to individual risk estimates could reduce blood collections from donors with low or absent iron stores.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWAR was funded by a Stanford Interdisciplinary Graduate Fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Stanford University waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe RISE dataset was accessed through the National Heart, Lung, and Blood Institute (NHLBI) Biolincc repository (https://biolincc.nhlbi.nih.gov). Our Research Materials Distribution Agreement prohibits publication of the raw data, but other researchers can submit a data request to NHLBI at no charge. https://www.doi.org/10.5281/ZENODO.5247221 ER -